SCHEMBL18649182

SCHEMBL18649182

CC(=O)OCCCNC(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
ADRB2 P07550 2/20 0.41
KDM4E B2RXH2 3/20 0.40
TDP1 Q9NUW8 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
CHRM5 P08912 2/20 0.39
CHRM1 P11229 2/20 0.39
CHRM3 P20309 2/20 0.39
PGR P06401 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
HTR1A P08908 1/20 0.39
CHRNB2 P17787 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18130385 0.94 ALDH1A1 (0.48) ALDH1A1ADRB2KDM4ETDP1SMN1; SMN2
SCHEMBL5950971 0.87 ALDH1A1 (0.43) ALDH1A1KDM4ETDP1SMN1; SMN2MEN1
Hydrochloric Acid SCHEMBL1067135 0.85 ALDH1A1 (0.41) ALDH1A1KDM4ETDP1SMN1; SMN2MEN1
SCHEMBL344691 0.81 TSHR (0.53) ALDH1A1ADRB2KDM4ETDP1SMN1; SMN2
SCHEMBL17036647 0.79 ALDH1A1 (0.48) ALDH1A1ADRB2KDM4ETDP1SMN1; SMN2
SCHEMBL67905 0.78 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2CHRM5CHRM1CHRM3
SCHEMBL454478 0.77 ALDH1A1 (0.35) ALDH1A1KDM4ETDP1SMN1; SMN2CYP1A2
SCHEMBL14557167 0.77 KDM4E (0.52) ALDH1A1KDM4ETDP1MEN1KMT2A
SCHEMBL345340 0.77 TSHR (0.57) ALDH1A1ADRB2KDM4ETDP1TSHR
SCHEMBL17036668 0.77 DGKA (0.44) ALDH1A1ADRB2KDM4ETDP1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9598446-B2 Amino compounds for treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2017-03-21 US disclosed